Tiziana Life Sciences (LON:TILS) shares hit a new 52-week low during mid-day trading on Friday . The company traded as low as GBX 81 ($1.14) and last traded at GBX 82.50 ($1.16), with a volume of 10191 shares changing hands. The stock had previously closed at GBX 86.50 ($1.21).
Separately, Beaufort Securities reiterated a “speculative buy” rating and set a GBX 400 ($5.61) price objective on shares of Tiziana Life Sciences in a report on Tuesday, December 19th.
ILLEGAL ACTIVITY WARNING: “Tiziana Life Sciences (TILS) Sets New 1-Year Low at $81.00” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/08/tiziana-life-sciences-tils-sets-new-1-year-low-at-81-00.html.
Tiziana Life Sciences Company Profile
Tiziana Life Sciences plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus.
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.